Evidence map›Paper›PMID 40061566›Full record

ArticleNAR cancer2025

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Roderic Espín, Ferran Medina-Jover, Javier Sigüenza-Andrade, Sònia Farran-Matas, Francesca Mateo, Agnes Figueras, Rosario T Sanz, Guillermo Pablo Vicent, Arzoo Shabbir, Lara Ruiz-Auladell and 30 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Roderic EspínProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Ferran Medina-JoverProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Javier Sigüenza-AndradeProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Sònia Farran-MatasProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Francesca MateoProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Agnes FiguerasProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Rosario T SanzMolecular Biology Institute of Barcelona, Spanish National Research Council (IBMB-CSIC), Barcelona 08028, Spain.
Guillermo Pablo VicentMolecular Biology Institute of Barcelona, Spanish National Research Council (IBMB-CSIC), Barcelona 08028, Spain.ORCID 0000-0002-0554-2226
Arzoo ShabbirProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Lara Ruiz-AuladellProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Emilio Racionero-AndrésProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Irene GarcíaProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Alexandra BaigesProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Lídia Franco-LuzónProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Adrián Martínez-TebarProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Miguel Angel Pardo-CeaProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.ORCID 0000-0003-3222-4044
María Martínez-IniestaProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Xieng Chen WangProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Elisabet CuyàsProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Javier A MenendezProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Marta Lopez-CerdaOncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Purificacion MuñozOncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Ivonne RichaudRegenerative Medicine Program and Program for Clinical Translation of Regenerative Medicine in Catalonia-P-CMR[C], Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Angel RayaRegenerative Medicine Program and Program for Clinical Translation of Regenerative Medicine in Catalonia-P-CMR[C], Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Isabel FabregatOncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Alberto VillanuevaProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Xènia SerratModeling Human Diseases in C. elegans Group, Genes, Diseases, and Therapies Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Julián CerónModeling Human Diseases in C. elegans Group, Genes, Diseases, and Therapies Program, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Montserrat AlemanyOncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Inés GuixDepartment of Radiation Oncology and Helen Diller Family Comprehensive Cancer Centre, University of California San Francisco, San Francisco, CA 94115, United States.
Andrea Herencia-RoperoDepartment of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona 08193, Spain.
Violeta SerraExperimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona 08035, Spain.
Rehna KrishnanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Karim MekhailDepartment of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
Razqallah HakemPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
Jordi BrunaOncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Mary Helen Barcellos-HoffDepartment of Radiation Oncology and Helen Diller Family Comprehensive Cancer Centre, University of California San Francisco, San Francisco, CA 94115, United States.
Francesc ViñalsProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Álvaro AytesProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.
Miquel Angel PujanaProCURE, Catalan Institute of Oncology, L'Hospitalet del Llobregat, Barcelona 08908, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative end-joining (alt-EJ) is an error-prone DNA repair pathway that cancer cells deficient in homologous recombination rely on, making them vulnerable to synthetic lethality via inhibition of poly(ADP-ribose) polymerase (PARP). Targeting alt-EJ effector DNA polymerase theta (POLθ), which synergizes with PARP inhibitors and can overcome resistance, is of significant preclinical and clinical interest. However, the transcriptional regulation of alt-EJ and its interactions with processes driving cancer progression remain poorly understood. Here, we show that alt-EJ is suppressed by hypoxia while positively associated with MYC (myelocytomatosis oncogene) transcriptional activity. Hypoxia reduces

Indexed as

DNA End-Joining RepairGene Expression Regulation, NeoplasticNeoplasmsCell Line, TumorDNA-Directed DNA PolymeraseDNA Polymerase thetaHumansHypoxia-Inducible Factor 1, alpha SubunitPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProto-Oncogene Proteins c-mycDNA-Directed DNA PolymeraseDNA Polymerase thetaHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsProto-Oncogene Proteins c-myc

Identifiers

PMID40061566
PMCPMC11886861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.